Matthias Tacke

Biography

Working as professor at University college of Dublin, Ireland in Chemistry Department. Completed PhD in Chemistry 1987 Diplom in Chemistry, University of Münster, Germany 1990 Ph.D. in Inorganic Chemistry, University of Münster 1990 Postdoctoral Associate, University of München, Germany 1991 Postdoctoral Associate, University of Amsterdam, The Netherlands 1992-1996 Habilitation in Inorganic Chemistry, University of Karlsruhe, Germany  1996-2004 College Lecturer, Department of Chemistry, University College Dublin May 1997 Habilitation Colloquium, University of Karlsruhe 2002-2013 Conway Fellow Since 2005 Senior Lecturer, UCD School of Chemistry and Chemical Biology 2006-2007 Chairman of CESAR-AWO (Central European Society for Anticancer Drug Research) Autumn 2007 Visiting Professor at the ENSCP in Paris with Prof. Dr. Gerard Jaouen Oct. 2009 Winner of the CESAR Prize 2009 for Translational Anticancer Research Working as professor at University college of Dublin, Ireland in Chemistry Department. Completed PhD in Chemistry 1987 Diplom in Chemistry, University of Münster, Germany 1990 Ph.D. in Inorganic Chemistry, University of Münster 1990 Postdoctoral Associate, University of München, Germany 1991 Postdoctoral Associate, University of Amsterdam, The Netherlands 1992-1996 Habilitation in Inorganic Chemistry, University of Karlsruhe, Germany  1996-2004 College Lecturer, Department of Chemistry, University College Dublin May 1997 Habilitation Colloquium, University of Karlsruhe 2002-2013 Conway Fellow Since 2005 Senior Lecturer, UCD School of Chemistry and Chemical Biology 2006-2007 Chairman of CESAR-AWO (Central European Society for Anticancer Drug Research) Autumn 2007 Visiting Professor at the ENSCP in Paris with Prof. Dr. Gerard Jaouen Oct. 2009 Winner of the CESAR Prize 2009 for Translational Anticancer Research

Research Interest

research group is interested in synthesising novel carbene-metal antibiotics and titanocene anticancer drugs in order to evaluate them biologically in cell tests and mouse models. Additionally we want to get an insight into the mechanism of action from a biological and chemical point of view. The targets for our titanocenes are breast and renal cell cancer, while the carbene-metal antibiotics are to be developed into resistance-breaking antibiotics targeting difficult bacteria like MRSA.